Hepatotoxicity of Rifampicin and Pyrazinamide Treatment Excluding Isoniazid

Background : Even though two-month rifampicin (RMP, R) and pyrazinamide (PZA, P) treatment has some advantages over isoniazid (INH, H) treatment for latent tuberculosis infection (LTBI), it was withdrawn from the list of treatment regimens for LTBI because of reported cases of severe hepatotoxicity. The purpose of this study was to estimate the frequency of hepatotoxicity of RMP and PZA treatment excluding INH in a Korean population.Method : TIn order to recruit patients who were prescribed RMP and PZA excluding INH, 256 INH-resistant tuberculosis patients were investigated through retrospective medical record analysis. A standard four-drug regimen was changed to a RMP/PZA-containing regimen excluding INH in 64 patients (RZ+ group). In the same study period, 146 patients who were prescribed an INH/RMP/PZA-containing standard regimen were randomly selected as a control (HRZ+ group). Clinical characteristics including liver diseases and the frequency of drug-induced hepatitis were compared between the RZ+ and HRZ+ groups.Result : The mean age of patients in the RZ+ group was 50.2 (±16.2) and the male-to-female ratio was 36:28. The frequency of underlying liver diseases was 10.9% (7/64), which was not significantly different from that of the HRZ+ group (4.1%, 6/146). Even though the treatment duration of RZ+ (5.5 ± 4.8 months) was longer that than that of HRZ+ (2.7 ± 2.3 months), the frequency of toxic hepatitis was not significantly different between RZ+ and HRZ+ groups, 3.5% (2/57) and 7.1% (10/140), respectively.Conclusion : Hepatotoxicity was mild and occurred in a minor proportion of patients in a Korean population prescribed an RMP/PZA-containing regimen. A future prospective study including more patients is needed.(Tuberc Respir Dis 2006; 60: 38-43)

keywords

Reference

(2005) Guidelines for the control of tuberculosis, Korean National Institute of Health

(2004) Guideline for the treatment of latent tuberculosis infection in patients treated with TNF blockers, Korean Food and Drug Administration

(2002) Cost- effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities,

(1996) Rifampin preventive therapy for tuberculosis in Boston's homeless,

(2000) Targeted tuberculin testing and treatment of latent tuberculosis infection,

(2002) Update:fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection,

(2001) Update:fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection,and revisions in American Thoracic Society/CDC recommendations--United States,2001,

(2003) Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003,

(2002) Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis,

10.

(2002) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection:a multicenter clinical trial,

11.

(2000) Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons:an international randomized trial,

12.

(2002) Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners,

13.

(2003) Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis:improved completion rates but more hepatotoxicity,

14.

(2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America:treatment of tuberculosis,

15.

(2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis,

16.

(1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice,

17.

(2004) Hepatotoxicity of rifampicin and pyrazinamide combination treatment treatment with rifampicin and pyrazinamide containing regimen excluding isoniazid due to isoniazid resistance,

바로가기메뉴

Article Contents

Vol.60 No.1

Hepatotoxicity of Rifampicin and Pyrazinamide Treatment Excluding Isoniazid

Abstract

Reference

Tuberculosis & Respiratory Diseases